7 completed, 1 withdrawn. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
Follow TB-403: new trials by email Literature Review of TB-403 trials Research Report on TB-403
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1) THR-317 8mg - Retinal Telangiectasis, Idiopathic Juxtafoveal Retinal Telangiectasia | Phase 2 | Completed | ThromboGenics | 8 | 2018-09-18 | 2020-09-02 |
| A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME) Ranibizumab 0.5mg, THR-317 8mg, Sham injection - Diabetes Mellitus, Diabetic Retinopathy | Phase 2 | Completed | Oxurion | 70 | 2018-04-20 | 2019-08-02 |
| A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma TB-403 20mg/kg, TB-403 50mg/kg, TB-403 100mg/kg - Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS) | Phase 1 | Completed | Oncurious NV | 18 | 2016-05-01 | 2021-01-13 |
| 89Zr-RO5323441 PET Imaging in Glioblastoma Molecular imaging with 89Zr-RO5323441 - Glioblastoma | Phase 2 | Withdrawn | University Medical Center Groningen | 2014-09-01 | 2024-05-06 | |
| A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma RO5323441 + bevacizumab [Avastin], bevacizumab [Avastin] - Glioblastoma Multiforme | Phase 1 | Completed | Hoffmann-La Roche | 22 | 2011-05-01 | 2016-11-02 |
| A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma RO5323441, sorafenib - Carcinoma, Hepatocellular | Phase 1 | Completed | Hoffmann-La Roche | 6 | 2011-03-01 | 2016-11-02 |
| A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer RO5323441 - Colorectal Cancer, Ovarian Cancer | Phase 1 | Completed | Hoffmann-La Roche | 7 | 2010-05-01 | 2016-11-02 |
| Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours TB-403 - Solid Tumors | Phase 1 | Completed | BioInvent International AB | 21 | 2008-06-01 | 2022-03-16 |
Glioblastoma (2) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Diabetes Mellitus (1) · Diabetic Retinopathy (1) · Idiopathic Juxtafoveal Retinal Telangiectasia (1) · Macular Edema (1) · Medulloblastoma (1) · Neuroblastoma (1) · Ovarian Neoplasms (1) · Recurrence (1) · Retinal Telangiectasis (1) · Rhabdomyosarcoma, Alveolar (1) · Sarcoma, Ewing (1)
Hoffmann-La Roche (3) · BioInvent International AB (1) · Oncurious NV (1) · Oxurion (1) · ThromboGenics (1) · University Medical Center Groningen (1)
France (3) · Switzerland (3) · United Kingdom (3) · Belgium (2) · Denmark (2) · Spain (2) · Germany (1) · Netherlands (1) · Singapore (1) · Slovakia (1) · United States (1)
Annemiek M. Walenkamp, MD, PhD (1) · Dorthe Nielsen, MD, PhD (1) · Lena Winstedt, PhD (1) · Ulrik Lassen, MD, PhD (1)
2017 (2), 2009 (1)